HSCSNasdaqFinance ServicesFiscal year ends April 30Also trades as HSCSW
HeartSciences Inc.
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 14, 2026
$3.07+0.05 (+1.66%)
Close on Oct 19, 2026
- Market cap
- $11.26M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Margins
Share of revenue, fiscal years 2021 to 2026
Gross margin
59.1%
Operating margin
-194787.4%
Net margin
-211666.5%
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -0.7% | -5.7% | – | – | |
| Gross profit | +3.3% | +2.7% | – | – |
Returns and balance sheet
6 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2021 | FY2021 | FY2026 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | -4239.9% | |
| Return on assets | – | – | -192.8% | |
| Current ratio | – | – | 0.53 | |
| Debt to equity | – | – | 0.00 | |
| Interest coverage | – | – | -11.2× | |
| Inventory turnover | – | – | 0.0× | |
| Capex to revenue | – | – | 82.3% | |
| Diluted shares | – | – | 3M |
Where the cash went
Fiscal 2022 to 2026, five years combined
HeartSciences generated $30.33M from operations and spent $91.41K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$30.33M
Used
$91.41K
Capital expenditure$91.41K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-211666.5%
×Asset turnover0.00×
×Equity multiplier22.00×
=Return on equity, FY2026-4239.9%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2026 | -211666.5% | 0.00× | 22.00× | -4239.9% |
| FY2025 | -201499.5% | 0.00× | 1.82× | -233.0% |
| FY2024 | -35511.9% | 0.00× | 1.69× | -175.0% |
| FY2023 | -123384.3% | 0.00× | -0.92× | 218.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
3of 9 tests passed in fiscal 2026. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$9.14M
- Cash generatingOperating cash flow above zero-$7.43M
- Return on assets improvedROA up on the prior year-92.2% → -216.5%
- Earnings backed by cashOperating cash flow above net income-$7.43M vs -$9.14M
- Less leverageLong-term debt to assets fell0.0% → 0.0%
- Better liquidityCurrent ratio rose0.59 → 0.53
- No dilutionShare count did not rise1M → 3M
- Gross margin improvedGross margin up on the prior year56.78% → 59.06%
- More efficientAsset turnover rose0.00 → 0.00